US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Spermosens year-end status update: Strong progress and promising outlook for 2025

Spermosens AB (“Spermosens” or the “Company”) provides a year-end update on its progress in 2024, a transformative year marked by key achievements, new leadership and the execution of a revised strategy that has positioned the Company for success going forward.Spermosens continues to advance its unique and patented JUNO-Checked technology, designed to transform male fertility diagnostics. The technology measures sperm cells' ability to bind to the egg, a crucial factor in fertilization. This provides a more accurate and meaningful assessment of male fertility, which is essential for

Spermosens announces the last day of trading in BTU and the first day of trading in warrants series TO 5 and TO 6

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE   The rights issue of units that was announced on 3 October 2023 (the "Rights Issue") in Spermosens AB (publ) ("Spermosens" or the "Company") has been registered with the Swedish Companies Registration Office (Sw.

Spermosens carries out directed issues of approx. MSEK 5.59, takes up credit facility of MSEK 1.00, and receives proposal of directed issues of approx. MSEK 0.39

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, NEW ZEALAND, JAPAN, HONG KONG, SOUTH KOREA, SINGAPORE, SOUTH AFRICA, SWITZERLAND, RUSSIA OR BELARUS OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE. The Board of Directors (the “Board”) of Spermosens AB (publ) (“Spermosens” or the “Company”) has today decided to carry out directed issues of shares and warrants pursuant to the authorization granted by the extraordinary

Spermosens announces positive results from ongoing clinical study

Spermosens AB ("Spermosens" or the "Company") is pleased to announce the first interim results from its ongoing clinical study aimed at validating the diagnostic value of the patented JUNO-Checked system. The study is progressing as planned, and the first results are now being presented according to schedule. The first interim results from the clinical study show a positive correlation between higher JUNO scores, which measure the sperm cells' binding capacity to the egg, and increased fertilization rates and pregnancy outcomes following IVF treatments. JUNO-Checked, the first-ever method to

Spermosens publishes outcome in rights issue

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE   On 3 October 2024, Spermosens AB (publ) (“Spermosens” or the “Company”) announced a rights issue of units of approximately SEK 22.7 million (the “Rights Issue”). The subscription period of the Rights Issue ended on 25

The subscription period in Spermosens’ rights issue of units ends on Monday, 25 November 2024

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE   Monday, 25 November 2024, is the last day of the subscription period in Spermosens AB:s (publ) (“Spermosens” or the “Company”) issue of a maximum of 283,607,120 units, corresponding to a maximum of 2,268,856,960 shares,

Spermosens' commercial strategy targets billion-dollar sperm bank market through global partnerships

Spermosens AB ("Spermosens" or the "Company") is pleased to provide an update on its progress in securing commercial partnerships and licensing agreements for its unique and patented JUNO-Checked system, designed to address critical unmet needs in male fertility diagnostics. As part of its commercial strategy, the Company is actively pursuing partnerships in key markets, including the United States, Europe, Japan and South Korea, through licensing agreements. These efforts include addressing the billion-dollar sperm bank market by partnering with major sperm banks, leveraging Spermosens’

Spermosens provides update on clinical study progress

Spermosens AB ("Spermosens" or the "Company") is pleased to provide an update on its ongoing clinical study at Reproductive Medicine Center (RMC) in Malmö. This study, which evaluates the diagnostic relevance of the second-generation JUNO-Checked technology, is a significant step toward advancing personalized IVF treatments and supporting sperm banks in identifying the best possible donors. The second-generation JUNO-Checked offers improved performance and a shorter readout time, enhancing the accuracy and efficiency of the analysis.Now in its sixth week, the study has received strong

The subscription period in Spermosens’ rights issue of units begins today

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE   Today, 11 November 2024, is the first day of the subscription period in Spermosens AB:s (publ) (“Spermosens” or the “Company”) issue of a maximum of 283,607,120 units, corresponding to a maximum of 2,268,856,960 shares,

Spermosens publishes information memorandum due to upcoming rights issue of units

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE   The Board of Directors of Spermosens AB (publ) ("Spermosens" or the "Company") has, in connection with the Company's upcoming rights issue of units that was announced on 3 October 2024 (the "Rights Issue"), prepared an

Spermosens announces advancements in second-generation JUNO-Checked system

Spermosens AB ("Spermosens" or the "Company") is pleased to share additional information on the enhanced capabilities of its second-generation JUNO-Checked system, a significant advancement in male fertility diagnostics. JUNO-Checked is the first device that enables clinicians and researchers to measure sperm binding capacity - a critical parameter that complements current analyses in IVF clinics and provides deeper insights into male fertility.The second-generation JUNO-Checked system builds on the strengths of the initial platform, introducing enhancements in sensitivity, accuracy and

Announcement from the Extraordinary General Meeting of Spermosens AB (publ)

Spermosens AB ("Spermosens" or the "Company") held an Extraordinary General Meeting today, 4 November 2024. At the meeting, the shareholders approved all previously announced proposals. The decisions can be summarized as follows: The meeting resolved to reduce the share capital without cancelling shares, to cover losses, through an amendment of the Articles of Association and a decision to reduce the share capital. The new limits for the share capital are a minimum of SEK 560,000 and a maximum of SEK 2,240,000. The number of shares will be between 280,000,000 and 1,120,000,000.

Spermosens reduces spending by focusing on clinical study and business development

Spermosens AB ("Spermosens" or the "Company") is pleased to announce updates to its cost structure following the revised strategy. Over the past months, the Company has effectively adapted the organization to align with a new focus on the clinical study and business development, reducing overall spending and investment needs by more than 50%.As part of its strategic initiatives, Spermosens has concentrated resources on its clinical study and on building strategic partnerships for commercialization. With the introduction of the second-generation JUNO-Checked technology, the Company can now

Spermosens AB (publ)INTERIM REPORT JANUARY - SEPTEMBER 2024

Strong progress in clinical study1 JANUARY – 30 SEPTEMBER 2024 SIGNIFICANT EVENTS DURING THE QUARTER   · Spermosens next-generation male fertility diagnostic product ready for clinical study · Spermosens has entered into an agreement with US based ScanMed Partners to identify and attract strategic and commercial partners in North America with special focus on the US market · Spermosens passes an important milestone receiving approval for significant clinical study       SIGNIFICANT EVENTS AFTER THE END OF THE INTERIM PERIOD · Kallelse till extra bolagsstämma

Spermosens reports strong progress in clinical study

Spermosens AB ("Spermosens" or the "Company") is pleased to announce strong progress in its ongoing clinical study at Reproductive Medicine Center (RMC) in Malmö, where the Company is evaluating its innovative JUNO-Checked technology. The study, designed to demonstrate the diagnostic relevance of JUNO-Checked in addressing male infertility, is progressing ahead of expectations with a strong recruitment rate.The excellent collaboration between Spermosens and RMC has played a key role in exceeding recruitment goals, with couples now being enrolled at a faster pace than initially expected. The

Spermosens signs memorandum of understanding for commercial partnership in Japan

Spermosens AB ("Spermosens" or the "Company") is pleased to announce the signing of a Memorandum of Understanding (MoU) with a well established undisclosed Japanese company to explore a commercial partnership in Japan. This MoU lays the framework and intentions for discussions regarding the distribution and commercialization of Spermosens' fertility diagnostic product, JUNO-Checked, in Japan. Potential avenues include a licensing agreement or joint venture.JUNO-Checked is Spermosens' innovative and proprietary diagnostic product designed to assess male fertility. This solution is believed

Spermosens receives notice of allowance for broad US patent covering JUNO-Checked technology

Spermosens AB (publ) (“Spermosens” or the “Company”) is pleased to announce that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the Company's second patent in the US, covering its innovative JUNO-Checked technology. The newly allowed patent, "Biosensor for Male Infertility" (Application no. 17/260,609), encompasses a broader range of claims compared to Spermosens' first US patent. This patent includes claims for a biosensor utilizing the JUNO protein immobilized on a variety of substrates, significantly expanding the scope beyond the previously

Spermosens recruits first couple for clinical study on next-generation male fertility diagnostic product

Spermosens AB (“Spermosens” or the “Company”) is pleased to announce a significant milestone in its clinical study of the next-generation fertility diagnostic product. The first couple has now been recruited for the study, which is designed to assess the diagnostic value of JUNO-Checked in male infertility. The clinical study, currently underway at the Reproductive Medicine Center (RMC) in Malmö, follows ethical approval for the study. Spermosens’ next-generation device, developed in collaboration with Flex Medical Solutions (FMS), features improved performance and faster read-out times,

Spermosens carries out a rights issue of units of approximately SEK 22.7 million

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE   Today, the board of directors in Spermosens AB (publ) (“Spermosens” or the “Company”) has, subject to approval by the extraordinary general meeting on 4 November 2024, resolved to carry out an issue of 283,607,120 units,

Spermosens next-generation male fertility diagnostic product ready for clinical study

Spermosens AB ("Spermosens" or the "Company") is pleased to announce the development of the next-generation of its JUNO-Checked device, a groundbreaking product designed to assess male fertility potential. Developed in collaboration with Flex Medical Solutions (FMS), this next-generation JUNO-Checked device will play a pivotal role in the upcoming clinical study, which has recently received ethical approval to be conducted at Reproductive Medicine Center (RMC) in Malmö. The new product generation offers enhanced performance, including faster read-out times, strengthening its ability to

Spermosens passes an important milestone receiving approval for significant clinical study.

Spermosens AB announces that the Swedish Ethical Review Authority has given approval for the company’s application to start a clinical study at Reproductive Medicine Center (RMC) in Malmö with JUNO-Checked to evaluate sperm quality for couples undergoing fertility treatment. This means that the company now takes the next step in validating diagnostic use of JUNO-Checked.Spermosens recently announced a revised strategy to accelerate the development and commercialisation of the unique JUNO-Checked product designed to address male infertility, with a clinical study conducted at RMC as a

Spermosens AB (publ) INTERIM REPORT JANUARY - JUNE 2024

The revised strategy positions Spermosens optimally to unlock the full potential of its groundbreaking product. Spermosens AB's interim report for the period January - June 2024, is now available on the Company's website and attached to this press release.1 JANUARY – 30 JUNE 2024 SIGNIFICANT EVENTS DURING THE QUARTER   · Spermosens receives patent approval in Singapore · The rights issue carried out during the month of April provided the company with SEK 24.2 million before issue costs, which amount to approximately SEK 7.0 million · Spermosens appoints Tore Duvold as new

Spermosens accelerates its US business development activities in collaboration with Scan MedPartners

Spermosens is accelerating its business development activities and has entered into an agreement with US based Scan MedPartners as its business development advisor to identify and attract potential strategic and commercial partners in North America with a special focus on the US market.As previously communicated, Spermosens is focused on securing licensing and co-development partners for its first of kind automated sperm diagnostic device JUNO-Checked. In line with this effort, Spermosens today announces a collaboration with Scan MedPartners, thereby significantly strengthening the company'

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe